“…[11][12][13][14] As also observed by Mooney et al 14 , the reversal of the increasing trend of serogroup C related IMD was simultaneous with the timing of MCC introduction and, therefore, likely attributable to it. The impact of MCC was investigated in many other European and Italian regional studies [14][15][16][17][18][19][20][21][22][23][24][25] which showed an important decrease in N. meningitidis C related IMD and a vaccine effectiveness as high as 100% depending on the age group and on the time elapsed from vaccination. A downward trend in serogroup C related IMD was also confirmed by the European Center for Disease Prevention and Control (ECDC) in countries with MCC vaccination.…”